Fabrizio Giordanetto
Fabrizio Giordanetto has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
Andreas Wållberg
4 shared publicationsLaurent Knerr
3 shared publicationsAnders Lindqvist
2 shared publicationsAnnika Åstrand
2 shared publications- Christian Tyrchan
AstraZeneca (Sweden)
2 shared publications Emma Lindhardt
2 shared publications
Latest Publications
- 8 November 2012
- Published by Informa Healthcare in Expert Opinion on Therapeutic Patents
- Vol. 22 (12) , 1467-1477
Direct AMP-activated protein kinase activators: a review of evidence from the patent literature
Introduction: AMP-activated protein kinase (AMPK), a heterotrimeric protein complex with serine/threonine kinase activity has a central role in controlling cellular energy expenditure. Small molecule-based activation of AMPK represents an attractive therapeutic proposition because of AMPK's ability to regulate several anabolic and catabolic pathways that are critical to the development of metabolic disorders and cancer. Areas covered: A comprehensive review of published patents that disclose direct AMPK activators is provided: 26 patents comprising 10 chemical classes, and supporting in vitro and in vivo data are discussed. Expert opinion: AMPK activation holds promise as a possible pharmacological intervention in several disease states. The development of direct, highly specific AMPK activators is necessary to fully realize the opportunities linked to AMPK activation and appreciate the risks associated with it.
- 8 November 2012
- Published by Informa Healthcare in Expert Opinion on Therapeutic Patents
- Vol. 22 (12) , 1467-1477
Direct AMP-activated protein kinase activators: a review of evidence from the patent literature
Introduction: AMP-activated protein kinase (AMPK), a heterotrimeric protein complex with serine/threonine kinase activity has a central role in controlling cellular energy expenditure. Small molecule-based activation of AMPK represents an attractive therapeutic proposition because of AMPK's ability to regulate several anabolic and catabolic pathways that are critical to the development of metabolic disorders and cancer. Areas covered: A comprehensive review of published patents that disclose direct AMPK activators is provided: 26 patents comprising 10 chemical classes, and supporting in vitro and in vivo data are discussed. Expert opinion: AMPK activation holds promise as a possible pharmacological intervention in several disease states. The development of direct, highly specific AMPK activators is necessary to fully realize the opportunities linked to AMPK activation and appreciate the risks associated with it.
- 1 November 2012
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 22 (21) , 6671-6676
Discovery of phosphoinositide 3-kinases (PI3K) p110β isoform inhibitor 4-[2-hydroxyethyl(1-naphthylmethyl)amino]-6-[(2S)-2-methylmorpholin-4-yl]-1H-pyrimidin-2-one, an effective antithrombotic agent without associated bleeding and insulin resistance
- 1 November 2012
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 22 (21) , 6671-6676
Discovery of phosphoinositide 3-kinases (PI3K) p110β isoform inhibitor 4-[2-hydroxyethyl(1-naphthylmethyl)amino]-6-[(2S)-2-methylmorpholin-4-yl]-1H-pyrimidin-2-one, an effective antithrombotic agent without associated bleeding and insulin resistance
- 11 June 2012
- Published by American Chemical Society (ACS) in Journal of Chemical Information and Modeling
- Vol. 52 (6) , 1480-1489
Exploiting Structural Information in Patent Specifications for Key Compound Prediction
- 11 June 2012
- Published by American Chemical Society (ACS) in Journal of Chemical Information and Modeling
- Vol. 52 (6) , 1480-1489
Exploiting Structural Information in Patent Specifications for Key Compound Prediction
- 1 September 2011
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 21 (18) , 5557-5561
Discovery of N-(1-adamantyl)-2-(4-alkylpiperazin-1-yl)acetamide derivatives as T-type calcium channel (Cav3.2) inhibitors
- 1 September 2011
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 21 (18) , 5557-5561
Discovery of N-(1-adamantyl)-2-(4-alkylpiperazin-1-yl)acetamide derivatives as T-type calcium channel (Cav3.2) inhibitors
- 1 August 2011
- Published by Elsevier in Drug Discovery Today
- Vol. 16 (15-16) , 722-732
Follow-on drugs: How far should chemists look?
- 1 August 2011
- Published by Elsevier in Drug Discovery Today
- Vol. 16 (15-16) , 722-732
Follow-on drugs: How far should chemists look?
- 1 January 2011
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 21 (2) , 829-835
Discovery of novel class 1 phosphatidylinositide 3-kinases (PI3K) fragment inhibitors through structure-based virtual screening
- 1 January 2011
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 21 (2) , 829-835
Discovery of novel class 1 phosphatidylinositide 3-kinases (PI3K) fragment inhibitors through structure-based virtual screening
- 19 November 2010
- Published by Informa Healthcare in Expert Opinion on Therapeutic Patents
- Vol. 21 (1) , 85-101
T-type calcium channels inhibitors: a patent review
(2011). T-type calcium channels inhibitors: a patent review. Expert Opinion on Therapeutic Patents: Vol. 21, No. 1, pp. 85-101. doi: 10.1517/13543776.2011.536532
- 19 November 2010
- Published by Informa Healthcare in Expert Opinion on Therapeutic Patents
- Vol. 21 (1) , 85-101
T-type calcium channels inhibitors: a patent review
(2011). T-type calcium channels inhibitors: a patent review. Expert Opinion on Therapeutic Patents: Vol. 21, No. 1, pp. 85-101. doi: 10.1517/13543776.2011.536532
- 1 August 2007
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 17 (15) , 4232-4241
Discovery of cyclopentane- and cyclohexane-trans-1,3-diamines as potent melanin-concentrating hormone receptor 1 antagonists
- 1 August 2007
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 17 (15) , 4232-4241
Discovery of cyclopentane- and cyclohexane-trans-1,3-diamines as potent melanin-concentrating hormone receptor 1 antagonists